

## Next generation asthma therapy in India

13 June 2017 | News

**First case of Bronchial Thermoplasty (BT), a therapy to address the needs of patients with severe persistent, drug-resistant asthma, performed in India.**



Boston Scientific India announced the availability of Bronchial Thermoplasty (BT) Therapy indicated for the treatment of severe, persistent, drug-resistant asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long acting beta agonists. The first BT procedure was performed in Royal Care Hospital, Coimbatore.

The Bronchial Thermoplasty therapy helps clear the bronchial airways by delivering thermal energy to the smooth muscle. This process decreases constriction in the patient's airways and enables easier breathing, reducing the frequency and severity of asthma attacks for patients with severe, persistent, drug-resistant asthma.

Bronchial Thermoplasty is performed under moderate sedation on an outpatient basis. The first BT patient is a middle aged woman, who is suffering from severe, persistent, drug-resistant asthma for the past 30 years. She had recurrent asthma attacks and frequent emergency room visits despite her medication regimes.

Prabal Chakraborty, Vice President and Managing Director, Boston Scientific, India said that there are over 18 million estimated asthmatics in the country, for some of whom currently available medication has failed to provide any relief. The company's Bronchial Thermoplasty Therapy holds great promise to help address this need gap. Boston Scientific has sufficient evidence that shows Bronchial Thermoplasty is an effective therapeutic option for patients with severe persistent, drug-resistant asthma

Dr. Pattabi Raman, Head- Pulmonology Associates, Royal Care Super Specialty Hospital, who performed the first BT procedure stated that this is a ground-breaking solution which may provide a complementary treatment to severe, persistent, drug-resistant asthma patients in the country.

This therapy is recognized globally and has been well received in around 20 markets.